Search Results

There are 131319 results for: content related to: Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

  1. You have free access to this content
    Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 12, December 2013, Pages: 1535–1545, A.B. Kimball, K.A. Papp, Y. Wasfi, D. Chan, R. Bissonnette, H. Sofen, N. Yeilding, S. Li, P. Szapary, K.B. Gordon and on behalf of the PHOENIX 1 investigators

    Version of Record online : 20 DEC 2012, DOI: 10.1111/jdv.12046

  2. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters

    The Journal of Dermatology

    Volume 37, Issue 5, May 2010, Pages: 413–425, Manjula REDDY, Gisela TORRES, Thomas McCORMICK, Colleen MARANO, Kevin COOPER, Newman YEILDING, Yuhua WANG, Charles PENDLEY, Uma PRABHAKAR, Jackson WONG, Cuc DAVIS, Stephen XU and Carrie BRODMERKEL

    Version of Record online : 9 APR 2010, DOI: 10.1111/j.1346-8138.2010.00802.x

  3. Ustekinumab: Lessons Learned from Targeting Interleukin-12/23p40 in Immune-Mediated Diseases

    Annals of the New York Academy of Sciences

    Volume 1182, Issue 1, December 2009, Pages: 97–110, Michael Elliott, Jacqueline Benson, Marion Blank, Carrie Brodmerkel, Daniel Baker, Kristin Ruley Sharples and Philippe Szapary

    Version of Record online : 10 DEC 2009, DOI: 10.1111/j.1749-6632.2009.05070.x

  4. You have free access to this content
    Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

    Intervention Review

    The Cochrane Library

    Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi, Olivier Chosidow and Laurence Le Cleach

    Published Online : 22 DEC 2017, DOI: 10.1002/14651858.CD011535.pub2

  5. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years

    British Journal of Dermatology

    Volume 166, Issue 4, April 2012, Pages: 861–872, A.B. Kimball, K.B. Gordon, S. Fakharzadeh, N. Yeilding, P.O. Szapary, B. Schenkel, C. Guzzo, S. Li and K.A. Papp

    Version of Record online : 27 MAR 2012, DOI: 10.1111/j.1365-2133.2012.10901.x

  6. You have free access to this content
    Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

    Intervention Review

    The Cochrane Library

    John K MacDonald, Tran M Nguyen, Reena Khanna and Antje Timmer

    Published Online : 25 NOV 2016, DOI: 10.1002/14651858.CD007572.pub3

  7. You have free access to this content
    Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

    British Journal of Dermatology

    Volume 168, Issue 4, April 2013, Pages: 844–854, K.A. Papp, C.E.M. Griffiths, K. Gordon, M. Lebwohl, P.O. Szapary, Y. Wasfi, D. Chan, M.-C. Hsu, V. Ho, P.D. Ghislain, B. Strober, K. Reich and on behalf of the PHOENIX 1, PHOENIX 2 and ACCEPT Investigators

    Version of Record online : 25 MAR 2013, DOI: 10.1111/bjd.12214

  8. You have free access to this content
    Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial

    The Journal of Dermatology

    Volume 39, Issue 3, March 2012, Pages: 242–252, Atsuyuki IGARASHI, Takeshi KATO, Mai KATO, Michael SONG, Hidemi NAKAGAWA and THE JAPANESE USTEKINUMAB STUDY GROUP

    Version of Record online : 29 SEP 2011, DOI: 10.1111/j.1346-8138.2011.01347.x

  9. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies

    British Journal of Dermatology

    Volume 164, Issue 4, April 2011, Pages: 862–872, K. Reich, R.G. Langley, M. Lebwohl, P. Szapary, C. Guzzo, N. Yeilding, S. Li, M-C. Hsu and C.E.M. Griffiths

    Version of Record online : 4 APR 2011, DOI: 10.1111/j.1365-2133.2011.10257.x

  10. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data

    British Journal of Dermatology

    Volume 167, Issue s3, November 2012, Pages: 3–11, M.H.A. Rustin

    Version of Record online : 22 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11208.x

  11. You have free access to this content
    The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

    British Journal of Dermatology

    Volume 167, Issue 5, November 2012, Pages: 1145–1152, T.-F. Tsai, V. Ho, M. Song, P. Szapary, T. Kato, Y. Wasfi, S. Li, Y.K. Shen, C. Leonardi, on behalf of the PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups

    Version of Record online : 29 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11142.x

  12. Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue s5, August 2012, Pages: 2–8, Christopher E.M. Griffiths and Giampiero Girolomoni

    Version of Record online : 3 JUL 2012, DOI: 10.1111/j.1468-3083.2012.04604.x

  13. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases

    International Journal of Dermatology

    Volume 54, Issue 10, October 2015, Pages: 1194–1198, Naomi Takahashi, Shinji Noda, Takashi Taniguchi and Makoto Adachi

    Version of Record online : 27 MAY 2015, DOI: 10.1111/ijd.12859

  14. Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 7, July 2011, Pages: 851–857, L. Guenther, C. Han, P. Szapary, B. Schenkel, Y. Poulin, M. Bourcier, J.P. Ortonne and H.L. Sofen

    Version of Record online : 27 APR 2011, DOI: 10.1111/j.1468-3083.2011.04082.x

  15. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis

    Clinical and Experimental Dermatology

    Volume 39, Issue 6, August 2014, Pages: 696–707, Y. Meng, L. Dongmei, P. Yanbin, F. Jinju, T. Meile, L. Binzhu, H. Xiao, T. Ping and L. Jianmin

    Version of Record online : 14 JUL 2014, DOI: 10.1111/ced.12390

  16. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial

    British Journal of Dermatology

    Volume 162, Issue 1, January 2010, Pages: 137–146, M. Lebwohl, K. Papp, C. Han, B. Schenkel, N. Yeilding, Y. Wang and G.G. Krueger

    Version of Record online : 9 NOV 2009, DOI: 10.1111/j.1365-2133.2009.09491.x

  17. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

    British Journal of Dermatology

    Volume 168, Issue 5, May 2013, Pages: 990–998, E.M. Baerveldt, A.J. Onderdijk, D. Kurek, M. Kant, E.F. Florencia, A.S. Ijpma, P.J. van der Spek, J. Bastiaans, P.A. Jansen, J.W.J. van Kilsdonk, J.D. Laman and E.P. Prens

    Version of Record online : 25 APR 2013, DOI: 10.1111/bjd.12175

  18. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis

    British Journal of Dermatology

    Volume 167, Issue s3, November 2012, Pages: 12–20, J. Leman and A.D. Burden

    Version of Record online : 22 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11209.x

  19. Novel biologic therapies in development targeting IL-12/IL-23

    Journal of the European Academy of Dermatology and Venereology

    Volume 24, Issue s6, October 2010, Pages: 5–9, PCM Van De Kerkhof

    Version of Record online : 9 SEP 2010, DOI: 10.1111/j.1468-3083.2010.03830.x

  20. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives

    Annals of the New York Academy of Sciences

    Volume 1222, Issue 1, March 2011, Pages: 30–39, Newman Yeilding, Philippe Szapary, Carrie Brodmerkel, Jacqueline Benson, Michael Plotnick, Honghui Zhou, Kavitha Goyal, Brad Schenkel, Jill Giles-Komar, Mary Ann Mascelli and Cynthia Guzzo

    Version of Record online : 22 MAR 2011, DOI: 10.1111/j.1749-6632.2011.05963.x